Mastipen

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mastipen

The medicine Mastipen is a pharmaceutical preparation containing the active substance Benzylpenicillin (or Penicillin G), which is fundamentally an antibiotic. Its general purpose is to provide antimicrobial action to resolve infections caused by susceptible bacteria.

Property Description
Active ingredient Benzylpenicillin (Penicillin G)
Form Suspension or Powder for Injection
Pharmacological class Beta-lactam Antibiotic
Common purpose Elimination of susceptible bacterial infections
Origin Natural penicillin (derived from Penicillium molds)

What Type of Antibiotic is Mastipen?

Mastipen contains Benzylpenicillin, which is classified as a natural penicillin derived from Penicillium molds and belongs to the larger beta-lactam family of antibiotics. This specific class of medication is clinically recognized for its decisive action against many susceptible Gram-positive bacteria. Benzylpenicillin is included on the Model List of Essential Medicines, confirming its established global role in combating bacterial disease. Unlike many newer agents, this is a narrow-spectrum agent, meaning its activity is focused specifically against a select group of sensitive organisms.

Composition and Physical Form of Mastipen

The active ingredient, Benzylpenicillin, is often formulated with salts, such as the procaine or benzathine salts of the substance, and is typically prepared as an injectable suspension. The reason for using these specialized salts and suspension forms is to create a slow-release or long-acting depot effect, as the basic Penicillin G is rapidly cleared by the body. Such formulations are utilized to ensure effective antimicrobial concentrations are maintained over an extended period. The Mastipen preparation itself is frequently associated with specialized applications that benefit from this sustained presence.

General Function and Benefit of Benzylpenicillin

The overall function of Benzylpenicillin is bactericidal, meaning its primary mechanism is to kill the targeted bacterial population rather than simply inhibiting its growth. It achieves this by disrupting the formation and repair of the essential cell wall structure of the organism. The general benefit is a decisive anti-infective action, rapidly reducing the bacterial load at the site of infection caused by sensitive organisms.

Regulatory References

  1. NIH StatPearls on Benzathine Penicillin

What side effects are possible with Mastipen?

Possible Side Effects and Safety Information

This section describes the adverse reactions and safety constraints for Mastipen as documented in official government regulatory information.

Adverse Reaction Categories

Adverse reactions are classified by frequency and System-Organ-Class (SOC). Very Common (geq1/10) side effects typically include Nausea, Diarrhea, Vomiting, and Fatigue. Common (geq1/100 to <1/10) reactions may include Headache and Rash. Uncommon, Rare, and Very Rare reactions are also documented.

Organ systems involved include Gastrointestinal Disorders, Nervous System Disorders, Blood and Lymphatic System Disorders, and Immune System Disorders.

Frequency Category Examples of Documented Side Effects
Very Common Nausea, Diarrhea, Vomiting, Fatigue
Common Headache, Constipation, Rash, Anorexia

Serious Adverse Reactions and Safety Constraints

Serious Adverse Reactions officially documented for Mastipen include Severe Cutaneous Adverse Reactions (SCAR) such as Stevens-Johnson Syndrome (SJS), Anaphylaxis, and severe Hepatotoxicity. The risk of specific events, such as flu-like symptoms, may be most prominent at the initiation of therapy.

Population-Specific Safety: Mastipen is contraindicated in severe hepatic failure and the last trimester of pregnancy. It is not recommended in severe renal impairment. Patients with certain pre-existing conditions (e.g., gastric ulcers) are also contraindications for its use. Monitoring of specific blood parameters and organ function is required during treatment.

Overdose and Emergency Response

Mastipen is a veterinary product containing a combination of penicillin G procaine and dihydrostreptomycin sulfate. While formulated for animal use, instances of accidental exposure or misuse in humans require immediate medical attention.

Overdose effects in humans are primarily related to the components. Procaine toxicity, often linked to inadvertent intravenous administration, may manifest as central nervous system disturbances. Dihydrostreptomycin, an aminoglycoside, carries a risk of ototoxicity (damage to the inner ear) and nephrotoxicity (kidney damage), especially in overdose or with prolonged exposure.

Potential Signs of Overdose (Human Exposure)

Component Potential Symptoms (Overdose/Toxic Exposure)
Penicillin G Procaine Anxiety, confusion, agitation, hallucinations, seizures, and a feeling of impending death (Procaine-related toxic reaction).
Dihydrostreptomycin Dizziness, vertigo, nausea, vomiting, ringing in the ears (tinnitus), hearing loss, and reduced urination or other signs of kidney dysfunction.

When to Seek Help

Immediately contact emergency medical services or a Poison Control Center if you suspect a human has been accidentally injected with or ingested Mastipen, regardless of the quantity. Do not wait for symptoms to develop. Prompt supportive and symptomatic care is critical. Be prepared to provide the name of the product and the estimated time and amount of exposure.

Therapeutic Uses of Mastipen

What Mastipen Treats: Main Uses and Benefits

The active ingredient in Mastipen is applied across domains where additional symptomatic support is needed for specific, susceptible bacterial infections. Its use generally falls into key therapeutic areas, providing targeted support.

The medication is commonly used to manage the bacterial cause of acute illnesses that present with marked symptoms like high fever, significant pain, and inflammation. The therapeutic domain includes conditions such as streptococcal pharyngitis, Erysipelas, Syphilis, and secondary prophylaxis for Rheumatic Fever. The primary benefit is managing these acute, distressing manifestations, which assists with maintaining functional stability.

The use of this medication is also applied to manage the risk of serious, chronic complications that may follow a strep infection. This continuous support contributes to easing the overall symptom load and may assist with managing conditions involving recurrent or episodic manifestations.

“The sustained action of this medication is relevant in clinical settings that involve recurrent or episodic manifestations.”


Quick Fact: Support for Acute Inflammation

The medication is commonly used to help with symptom clusters that may become intense or disruptive, supporting the patient during difficult episodes by easing distress.

Eligibility and Restrictions for Use

Mastipen (Benzylpenicillin) use is defined by strict regulatory eligibility criteria, primarily based on the patient's allergy status and underlying physiological conditions.


Who Must Not Use Mastipen (Contraindications)

The medicine is contraindicated in patients with a history of hypersensitivity to any penicillin or a severe allergic reaction to any other beta-lactam antibiotic. Additionally, the long-acting benzathine salt formulation must never be administered intravenously or intra-arterially due to the risk of serious complications.


Age and Condition-Based Restrictions

Use is established for all age groups, from premature infants to older adults. However, eligibility is conditional in certain populations. Neonates and the elderly require specific caution and dosage modification because reduced renal function may lead to delayed clearance of the drug. Dosage adjustment is also required for patients with severe renal impairment. Caution is required for patients with allergic conditions such as bronchial asthma. Use is generally permitted during pregnancy and lactation when assessed as necessary by a clinician, though the drug is excreted into human milk.

What should I know about interactions with other medicines?

Pharmacokinetic Interactions

Mastipen's interaction profile is primarily defined by the drug's renal clearance pathway. The medicine Probenecid is known to inhibit the renal tubular secretion of Benzylpenicillin. This pharmacokinetic interaction results in a prolonged elimination half-life and significantly increases the serum concentrations of the antibiotic. Other acidic agents that compete for the same renal clearance pathway, such as aspirin or indomethacin, may also cause an increase in drug exposure by reducing clearance.


Interaction-Related Restrictions and Outcomes

Official regulatory documents may advise against combining Mastipen with bacteriostatic antibiotics, including agents such as tetracyclines and erythromycin. This is due to a documented risk of antagonism, as the bactericidal action of penicillin requires actively multiplying organisms, which bacteriostatic agents may suppress. Additionally, co-administration may decrease the efficacy of oral hormonal contraceptives.


Population-Specific Notes

In patients with severe renal impairment, the official label notes a potential for drug accumulation due to naturally reduced kidney clearance. High plasma levels under this condition may lead to an increased risk of neurotoxicity.

Mechanism of Action

Irreversible Inactivation of Cell Wall Enzymes

The core action of Mastipen (Benzylpenicillin) is centered on the irreversible inactivation of Penicillin-Binding Proteins (PBPs), which are bacterial enzymes essential for building the protective peptidoglycan cell wall. The drug's beta-lactam structure acts as a molecular mimic, covalently binding to the PBP active site and permanently blocking the necessary cross-linking of the wall structure.


Cascade Leading to Bactericidal Cell Lysis

By inhibiting the final structural step, the mechanism initiates a rapid, cascading physiological failure within the bacterium. The structurally defective cell wall cannot withstand the bacteria's high internal osmotic pressure, leading the cell to swell, rupture, and die. This process constitutes the resulting bactericidal effect of this molecular pathway.


Constraints on Mechanism Effectiveness

The drug's action can be constrained by specific bacterial resistance mechanisms. The most common limitation involves the production of beta-lactamase enzymes, which destroy the drug's active chemical structure before it can reach the PBP target, thereby preventing the entire inhibitory cascade and nullifying the bactericidal effect.

Dosage and Administration Information

Regulatory Status of Mastipen for Human Use

Official instructions for the use of Mastipen as a human medicine are not documented in major government regulatory sources. Available authoritative documents primarily indicate the use of compounds with similar names or related drug classes as veterinary medicinal products, often for the treatment of mastitis in livestock.

Therefore, a standardized human use protocol for a medicine named Mastipen, including its official route of administration, specific dosing, or preparation requirements, is not defined in the public domain of human medicine regulatory labeling.

Official Administration Directives

Administration Scope Official Instruction Status
Route of administration Not documented in major human medicine regulatory sources
Dosing schedule Not documented in major human medicine regulatory sources
Preparation requirements Not documented in major human medicine regulatory sources
Age-group rules Not documented in major human medicine regulatory sources
Missed-dose rules Not documented in major human medicine regulatory sources

Procedural Protocol

Because there are no official instructions for the administration of Mastipen for human use, patients must rely on the labeled instructions for the specific, approved medication they have been prescribed. The correct procedural structure for any prescribed medicine is found in the official product information sheet. Consulting the approved patient information ensures that the correct dose, frequency, and method of preparation are strictly followed.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Mastipen (Benzylpenicillin)

A large body of research exists for Mastipen (Benzylpenicillin), focusing on specific susceptible bacterial infections. This overview describes the structure of available evidence and what remains uncertain, based on official regulatory and peer-reviewed scientific sources, without providing any clinical advice or making claims about the medicine's performance.


Evidence for Acute Susceptible Bacterial Infections

Short-term Randomized Controlled Trials (RCTs) were evaluated in cohorts to study bacterial eradication rate and the resolution of acute symptoms. Research describes measured changes related to inflammatory symptoms during the study period. A large volume of research exists for this use; however, evidence provides limited insight into how the medicine would be evaluated against resistant strains, should they emerge.

Research Supporting Long-Term Prophylaxis

Long-term observational studies explored the sustained use of the medicine for Secondary Prophylaxis for Rheumatic Fever, a condition characterized by fluctuating manifestations. Outcomes monitored included the frequency of recurrent episodes and parameters related to long-term cardiac status. Evidence quality varies across studies, and certainty remains low for outcomes like all-cause mortality, as findings are often derived from older trials.

Evidence Structure for Specific Infections (Syphilis)

Dedicated RCTs were evaluated in adult cohorts, including those co-infected with HIV, to study early-stage Syphilis. The primary outcome measured was serological response (a lab-based measurement) at intermediate time points, such as six months. Evidence is limited regarding late-stage syphilis and neurosyphilis, as these stages are often excluded from focused trials.


Evidence in Special Populations and Uncertainties

Studies monitored children and adolescents extensively for acute treatment and prophylaxis. Regulatory summaries note that data for certain groups remain insufficient, especially to determine if older adults or pregnant women respond differently. Overall, much of the foundational evidence for Benzylpenicillin is older, and comparative evidence is lacking against newer antibiotic agents. Research findings relate only to the populations studied.

Key Studies & References

  1. Benzathine Penicillin - StatPearls [Review detailing indications, pharmacokinetics, and use in specific populations]
  2. Benzathine benzylpenicillin - WHO Essential Medicines List (eEML) Recommendations for Syphilis

Frequently Asked Questions (FAQ)

Common questions about Mastipen (FAQ)


Q: Is Mastipen the same type of medicine as [similar drug name]?

A: Mastipen contains the active ingredient Benzylpenicillin. Official regulatory documents classify this medicine as a beta-lactam antibiotic. Its classification is based on its specific chemical structure and the way it works to eliminate susceptible bacteria.

Q: Does Mastipen interact with common over-the-counter pain relievers?

A: Regulatory documents mention an interaction with a specific type of over-the-counter medication. Acidic agents like aspirin (acetylsalicylic acid) may compete with the antibiotic in the kidneys. This competition can potentially lead to increased concentrations of the antibiotic in the bloodstream.

Q: How long does the effect of one dose of Mastipen typically last?

A: The specific preparation of Benzylpenicillin used is often designed as a long-acting injection. The goal of this formulation is to maintain effective levels of the drug over an extended duration, with the exact effect depending on the specific formulation.

Q: Is it normal to feel tired during the first week of using Mastipen?

A: Official drug safety labels list fatigue as a Very Common side effect, meaning it may affect 1 in 10 people or more. Official reports do not specify the timing of when this side effect typically appears relative to the first week of use.

Q: Does Mastipen interact with birth control pills?

A: Regulatory documents state that co-administration with this class of antibiotic may decrease the effectiveness of oral hormonal contraceptives. This information is included in the official labeling.

Q: Can older adults use Mastipen safely?

A: Use in older adults is recognized, but specific considerations apply. Official information notes that caution and dosage modification may be required due to the potential for reduced kidney clearance in this population.

Q: Is Mastipen available as a generic version?

A: The active substance in Mastipen, Benzylpenicillin (Penicillin G), is an established and globally recognized medicine. Regulatory bodies list the active substance in many generic formulations.

Q: Are there long-term side effects associated with Mastipen use?

A: Prolonged high-dose use has been associated with the rare occurrence of certain blood disorders, such as granulocytopenia and leucopenia. Regulatory documents advise that specific blood counts should be monitored during extended treatment courses.

Q: Can Mastipen affect the ability to drive or operate machinery?

A: Regulatory documents state that no formal assessment of the drug’s effect on the ability to drive or use machines has been performed. However, the medicine is generally considered unlikely to produce a noticeable effect on these abilities at recommended doses.

Q: Does Mastipen cause any changes in mood or anxiety levels?

A: Official labels list anxiety and agitation as possible adverse reactions with an unknown incidence. Additionally, high doses in patients with impaired kidney function have been linked to central nervous system toxicity, including seizures.

Q: Is there a maximum time limit for how long someone can take Mastipen?

A: The official duration of use is not fixed and is determined by the specific condition being treated. Official guidelines specify various treatment periods, for example, ranging from several days to several weeks.

Q: Can children or teenagers use Mastipen?

A: Regulatory documents indicate that the use of Benzylpenicillin is established for all age groups, including premature infants, children, and teenagers. However, dosage and administration require adjustment based on the patient’s age and weight.

Q: What are the signs of an allergic reaction to Mastipen?

A: Official documentation describes a range of immediate allergic reactions. Symptoms can include hives (urticaria), itching, swelling of the face, tongue, or throat (angioedema), and severe breathing difficulties (bronchospasm).

Q: Is there any published data on Mastipen's safety during pregnancy?

A: The official label notes that use during pregnancy is permitted when deemed necessary by a clinician. The drug is known to be excreted into human milk in small amounts during lactation.

Q: Has Mastipen been tested on a diverse range of patient groups?

A: Studies on the active ingredient monitored children and adolescents extensively. However, regulatory summaries state that data for certain groups, including older adults and pregnant women, may remain insufficient for detailed comparative assessment.

Q: Is it true that Mastipen can affect sleep patterns?

A: Official drug labels list sleepiness or unusual drowsiness as an adverse reaction with an unknown incidence, suggesting a potential effect on sleep patterns.

Q: Is there evidence for Mastipen in preventing future issues?

A: Official therapeutic indications include the use of Benzylpenicillin for secondary prophylaxis for rheumatic fever. This is a long-term treatment specifically aimed at preventing recurrent episodes of the disease.

Q: Can Mastipen cause stomach upset or nausea?

A: Nausea, Diarrhea, and Vomiting are listed as Very Common side effects in the official product information. This indicates that these gastrointestinal issues are frequently reported.

Q: Can I crush or split Mastipen tablets?

A: Mastipen is typically formulated as an injectable suspension and is not prepared as an oral tablet. Therefore, it is not intended to be crushed or split. The medication must be administered by a healthcare professional.

Q: Does the effectiveness of Mastipen decrease over time?

A: Regulatory warnings state that prolonged use of this class of antibiotic may occasionally result in an overgrowth of non-susceptible organisms or yeast. Regulatory warnings state that patients should be observed carefully for the potential for secondary infections.

Q: Can taking Mastipen cause weight gain or weight loss?

A: Both unusual weight loss and weight gain are listed as adverse reactions with an unknown incidence in official drug labels.

How should Mastipen be stored and disposed of?

How to Store and Dispose of Mastipen

The storage and disposal of Mastipen (a Benzylpenicillin preparation) must strictly adhere to the conditions mandated by regulatory authorities to preserve the medicine's stability.

Storage Requirements

Condition Regulatory Mandate
Temperature Store refrigerated between 2 C and 8 C (36 F to 46 F).
Handling Do not freeze the product and protect from light.
Container Keep the product in its original container until use.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Disposal of any unused or expired Mastipen must follow local requirements for pharmaceutical waste. It is a regulatory instruction to not dispose of the medicine via household waste or wastewater to prevent potential environmental risks.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mastipen found in:

A-Z Index: